Kyowa Kirin Korea Co., Ltd.
🇰🇷South Korea
Clinical Trials
7
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (33.3%)Phase 2
1 (33.3%)Phase 3
1 (33.3%)Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Recruiting
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06206135
- Locations
- 🇰🇷
Jesus Hospital, Jeonju, Korea, Republic of
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
Recruiting
- Conditions
- FGF23-related Hypophosphataemic Rickets and Osteomalacia
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06202027
- Locations
- 🇰🇷
Choi Hyeokjun, Seoul, Korea, Republic of
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients
Recruiting
- Conditions
- Hyperphosphatemia
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06186934
- Locations
- 🇰🇷
Jesus Hospital, Jeonju, Korea, Republic of
An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
Completed
- Conditions
- Breast Cancer FemaleBreast Neoplasm Female
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 1300
- Registration Number
- NCT03433560
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Gangwon, Korea, Republic of
🇰🇷Bucheon Soonchunhyang University Hospital, Bucheon, Kyounggi, Korea, Republic of
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Kyoungsang, Korea, Republic of
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
Phase 3
Completed
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT02982005
- Locations
- 🇰🇷
Korea, Republic of, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found